🌐 last30days v3.16.0 · synced 2026-10-26

Ozempic vs Mounjaro: What the Community Says (/Last30Days)

Quick Verdict

Same gut hormone, different number of receptors, and the community has basically stopped treating them as equals. Ozempic (semaglutide) hits one target, GLP-1; Mounjaro (tirzepatide) hits two, GLP-1 and GIP, and the weight-loss numbers that keep getting quoted tell the story: roughly 15% body weight on semaglutide versus 20-21% on tirzepatide, a gap @TrueNorthPeps made blunt in a thread calling Ozempic "the weakest drug in its own class now." That gap isn't just internet math either, the head-to-head SURPASS-2 trial randomized 1,879 adults with type 2 diabetes across 40 weeks and found HbA1c fell by 2.01-2.30 percentage points on tirzepatide's three doses versus 1.86 on semaglutide 1mg, with Lilly's own clinical data page noting that comparison used Ozempic 1mg since the 2mg dose wasn't yet available. The 30-day conversation split cleanly: Mounjaro owns the UK policy fight (MPs branding its NHS rollout "unambitious," only 6% of eligible patients getting it) and the jaw-dropping transformation posts (r/Mounjaro's "1 year on mounjaro" hit 565 upvotes), while Ozempic owns the side-effect anxiety and the weird-science headlines - hair loss, nail trouble, alcohol aversion, anti-aging organ clocks. Novo Nordisk is swinging back with a COMPETE SWITCH study claiming Ozempic 2mg carries a 6% lower cardiovascular-event risk than switching to Mounjaro. As one r/Mounjaro commenter put it after 18 months and 112 lbs lost: "it's worked wonders for my A1C and glucose levels, when Ozemp[ic]" couldn't. Meanwhile, threads like r/Mounjaro's "Starting Mounjaro" keep popping up weekly as new patients ask the same onboarding questions the regulars have answered a hundred times over.

Ozempic

Novo Nordisk's COMPETE SWITCH data, presented at EASD 2026, claims Ozempic 2mg beats switching to Mounjaro on heart risk. That's the defensive play from the incumbent: a real-world analysis linking the escalated 2mg dose to a statistically significant 6% lower risk of major adverse cardiovascular events versus tirzepatide. The community sentiment on Ozempic is more divided than Mounjaro's - the wins are real but the complaint volume is loud.

On the strength side, patient testimony holds up: one r/Ozempic poster logged 40 kg (88 lbs) down and the thread scored 146 upvotes, a "little happy ozempic story" pulled 500 upvotes, and another r/Ozempic poster documented 21 lbs down in five months for diabetes, with side-by-side photo evidence driving 106 upvotes. @EricTopol amplified the science angle, noting semaglutide "consistently reduced proteomic organ age 2-4 years for the heart, artery, and kidney clocks across 5 placebo-controlled trials" (806 likes), and a @jacquehoward CNN segment on GLP-1s and reversing aging racked up 1.1M views and 33,880 likes. The alcohol-aversion angle got its own deep-dive video, "Something weird is happening to people on Ozempic," where a top comment hit 6,000 likes. On the clinical-caution front, dr.rickpescatore's TikTok on vitamin B1 for GLP-1 patients pulled nearly 90,000 views, a reminder that the "watch your nutrient levels" PSA circuit runs alongside the weight-loss hype.

The weaknesses are where Ozempic takes its lumps. A Gizmodo piece - "Hair Loss Was Just the Start. Ozempic Users Are Also Reporting Nail Trouble" - hit the Hacker News front page with 69 points and 78 comments, and the broader Side Effects conversation (hair, nails, gut, mood) is the connective tissue running through nearly every Ozempic thread this month. The underlying research has actual numbers now: a nearly 2,000-person study presented at EADV and covered by BBC Science Focus found GLP-1 users reported nail detachment more than four times as often as nonusers, and Healthline's writeup of the same data put nail discoloration at 46% of GLP-1 users versus 17% of nonusers, a gap that held even among people who lost comparable weight, suggesting it isn't just the weight loss itself causing it. The American Academy of Dermatology rounds out the dermatologic complaint list beyond nails and hair: injection-site irritation, premature skin aging, excessive sweating, and dry skin from reduced eating and drinking patterns. @MidwesternDoc hammered the rebound problem to 354 likes: "the weight often returns when you stop taking it... One study linked GLP-1 drugs like Ozempic to over 4X the risk of bowel obstruction." @Peggyxiv wrote a raw thread about quitting after two years: "I was nauseated, lethargic, gut paralysis, no appetite and I literally starved myself." @Blue____78 and @DianaVStone both piled onto the side-effect skepticism thread, echoing the "is this worth it" fatigue that's crept into the X conversation. And @TrueNorthPeps put the efficacy knock plainly - semaglutide's 14.9% average has now been beaten by four newer drugs.

Mounjaro

MPs branded the NHS Mounjaro rollout "unambitious" on October 23, warning only 6% of eligible patients will get it in three years. That Commons Health and Social Care Committee report drove the entire Mounjaro news cycle, picked up by The Independent, Sky News, and BBC News, which called the plan for 220,000 people by 2028 a "woefully small number." The actual eligibility mechanics behind that slow rollout are laid out by NHS Somerset ICB: patients needed a BMI of at least 40 plus four of five weight-related comorbidities to qualify in year one, with the threshold only loosening to a BMI of 35-39 with four or more comorbidities in years two and three, a phased criteria ladder that explains why so few people clear the bar early. NHS England's national guidance confirms NICE recommends tirzepatide for adults with obesity who also present with comorbidities like dyslipidaemia, hypertension, or cardiovascular disease, and NHS Cheshire and Merseyside notes prescribing was folded into the 2026/27 GP contract from April 1, 2026, still gated behind the same qualifying-criteria table. The drug's regulatory starting point goes back further than the NHS fight suggests, too: the MHRA authorized Mounjaro for weight management back in November 2023, for adults with a BMI of 30+ or 27-30 with weight-related health problems, meaning the clinical green light has been sitting there for roughly three years while the funding and access machinery ground slowly behind it. @radionewshub summarized the MPs' report's core demand: faster access, more consistent obesity care, and a national treatment pathway so the system doesn't widen health inequalities. The community sentiment on Mounjaro skews markedly more positive than Ozempic - it's the drug people post transformation photos about, and it's also the drug a steady stream of newcomers are asking about before they even start, judging by how often "Starting Mounjaro" threads resurface on r/Mounjaro.

The strengths are loud and quantified. r/Mounjaro's "1 year on mounjaro" hit 565 upvotes; "123 lbs gone - Mounjaro changed my life" scored 669; and "lost 30 kgs in 9 months with mounjaro" pulled 410. The dual-agonist efficacy keeps getting cited - a Wave Plastic Surgery explainer walks through the NEJM data showing 15% loss at 5mg climbing to ~21% at 15mg, and the SURPASS trial family backs that up clinically: Lilly's clinical data page shows SURPASS-2's 15mg arm posted a -1.7% HbA1c change from baseline against -1.9% for Ozempic 1mg, while a separate SURPASS-3 arm added further head-to-head weight data against insulin comparators. On YouTube, Steve Julien's "6 Mounjaro Benefits I didn't see coming" surfaced the non-scale wins, with a top comment at 196 likes: "Brain fog lifted... My cholesterol level normalized. My knee pain disappeared... 50 lbs down in 6 months." @GoodJuju77777 and @heydawnX both added their own non-scale-victory testimonials into that same wave of positive sentiment, while @moneytokez weighed in on the commercial angle as Lilly's numbers keep climbing. The financial market agrees it's winning commercially - a Polymarket market on whether Eli Lilly's Q3 Mounjaro sales top $10B sat at 90% odds.

The weaknesses cluster around access, dependency, and the same GLP-1-class safety scares. The "two-tier system" framing is the dominant complaint - @TheHonestDr flagged a "12-year rollout" timeline with alarm, and over a million people reportedly pay privately instead. The phased BMI-and-comorbidity eligibility table from NHS Somerset ICB is exactly the kind of fine print fueling that complaint, since patients just under the BMI 40 cutoff in year one simply wait. Dependency anxiety surfaced on TikTok, where @my.journey.with.marc admitted "I think I'm addicted to Monjaro" after losing 126 lbs (97 likes). And the vision-loss panic hit both drugs - @emmarichardson75 asked "Is Mounjaro turning people blind?" (43 likes), echoing the NAION concern raised across the GLP-1 class. The dermatologic side effects aren't Ozempic-exclusive either, the American Academy of Dermatology frames hair thinning, brittle nails, and dry skin as a class-wide GLP-1 issue rather than a semaglutide-only complaint. A separate supply-chain scare also brushed up against Mounjaro's name this month: pharmakaresolutions clarified that a 22-lot recall of compounded tirzepatide from Apothecary Pharma over sterility concerns is "NOT a recall of Mounjaro or Zepbound," a distinction the comments section (rmems-style patient chatter included) kept having to repeat as the headline traveled faster than the clarification.

Head-to-Head

The Bottom Line

Choose Ozempic if cardiovascular protection and the longest clinical track record matter more to you than peak weight-loss numbers, especially for type 2 diabetes. Novo Nordisk's COMPETE SWITCH analysis claims the 2mg dose carries a 6% lower MACE risk than switching to Mounjaro, and @EricTopol points to organ-age reductions across five placebo-controlled trials, but go in clear-eyed about the rebound effect @MidwesternDoc keeps flagging, the SURPASS-2 data showing tirzepatide's HbA1c edge even at matched doses, and about the broader Side Effects conversation that follows semaglutide users from hair loss to the newly-quantified nail detachment risk documented by Healthline and BBC Science Focus.

Choose Mounjaro if raw weight-loss ceiling is the priority and you can navigate access - its dual-agonist mechanism posts ~20-21% versus semaglutide's ~15%, and the r/Mounjaro transformation threads (123 lbs, 44 kg, 112 lbs lost) show up with hundreds of upvotes each. Just know the UK "two-tier system" fight means NHS access is scarce - only 6% of eligible patients in three years, gated behind a BMI 40+ with multiple comorbidities bar per NHS Somerset ICB's criteria - so many are paying privately, and if you're just now reading a "Starting Mounjaro" guide, expect the dose-titration and sourcing questions to dominate your first few weeks.

The emerging stack

The pattern the community is actually converging on isn't picking one forever - it's sequencing and switching between them. Multiple r/Mounjaro threads discuss "Moving from Mounjaro to Ozempic/Wegovy for maintenance" and "Wegovy 2.4 to Mounjaro 5mg switch," treating tirzepatide as the heavy-lifting weight-loss phase and semaglutide/Wegovy as the maintenance layer. Novo Nordisk's entire COMPETE SWITCH messaging is built around that switching behavior being common enough to study. The through-line voices here - @Peggyxiv, @MidwesternDoc, and the r/Mounjaro / r/Semaglutide regulars - frame it as one GLP-1 journey with multiple drugs, not a two-brand loyalty war.